Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | M6PR | P20645 | 2/20 | 0.44 |
| ▸ | MGAM | O43451 | 4/20 | 0.40 |
| ▸ | SI | P14410 | 4/20 | 0.40 |
| ▸ | G6PD | P11413 | 2/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070982 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15215703 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15121661 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL2505909 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15273797 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL24605082 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL1832193 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL15273793 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL13509342 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 | |
| SCHEMBL767128 | 1.00 | M6PR (0.44) | M6PRMGAMSIG6PDFUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013024905-A1 | COMBINATION DRUG OF ANTIBODY AGAINST LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA AND ANTIBACTERIAL AGENT | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024905-A1 | COMBINATION DRUG OF ANTIBODY AGAINST LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA AND ANTIBACTERIAL AGENT | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
| WO-2011102552-A1 | ANTIBODY AGAINST A BAND LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-08-25 | — | — | WO | disclosed |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-7018824-B2 | Mannosyl transfer with regeneration of GDP-mannose | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050221447-A1 | water soluble transferase enzyme polypeptides, coded by exogenous DNA; glycosylation | THE SCRIPPS RESEARCH INSTITUTE | 2005-10-06 | — | — | US | disclosed |
| US-6919440-B2 | Mannosyl transfer with regeneration of GDP-mannose | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-07-19 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-20030119090-A1 | Mannosyl transfer with regeneration of GDP-mannose | WONG CHI-HUEY (US) | 2003-06-26 | — | — | US | disclosed |
| US-6485930-B1 | Mannosyl transfer with regeneration of GDP-mannose | THE SCRIPPS RESEARCH INSTITUTE | 2002-11-26 | — | — | US | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| US-5783677-A | FORMING INTERMEDIATES BY TREATING 6-DEOXY-A-L-MANNOPYRANOSYL BROMIDE AND 2,3,4-TRI-O-BENZOATE WITH DIMETHYLSULFOXIDE, A BASE, AND A SOLVENT | PROCTER & GAMBLE PHARMACEUTICALS, INC. | 1998-07-21 | — | — | US | disclosed |
| US-5721217-A | 14-AMINOANDROSTANE COMPOUNDS AS INOTROPIC AGENT TREATING CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0720616-A1 | NOVEL DEOXY AND OXYGEN-SUBSTITUTED SUGAR-CONTAINING 14-AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-10 | — | — | EP | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| WO-1995008558-A1 | NOVEL DEOXY AND OXYGEN-SUBSTITUTED SUGAR-CONTAINING 14-AMINOSTEROID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-30 | — | — | WO | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | M6PR 2907/4885MGAM 165/4885SI 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.